Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Marrow Diseases | 1 | 2021 | 38 | 0.740 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 87 | 0.590 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2016 | 8 | 0.530 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1678 | 0.450 |
Why?
|
| Burkitt Lymphoma | 2 | 2024 | 146 | 0.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 137 | 0.380 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1424 | 0.370 |
Why?
|
| Translocation, Genetic | 2 | 2024 | 345 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 803 | 0.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 271 | 0.320 |
Why?
|
| Primary Myelofibrosis | 3 | 2018 | 50 | 0.310 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2022 | 284 | 0.300 |
Why?
|
| Fanconi Anemia | 2 | 2018 | 49 | 0.290 |
Why?
|
| Hodgkin Disease | 2 | 2021 | 293 | 0.280 |
Why?
|
| Neoplasms | 1 | 2021 | 2753 | 0.270 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 137 | 0.250 |
Why?
|
| Hemoglobinopathies | 1 | 2023 | 16 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 174 | 0.220 |
Why?
|
| Pityriasis Lichenoides | 1 | 2022 | 1 | 0.210 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2022 | 3 | 0.210 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 21 | 0.210 |
Why?
|
| Histiocytosis | 1 | 2022 | 19 | 0.200 |
Why?
|
| Herpesvirus 4, Human | 3 | 2022 | 663 | 0.200 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 44 | 0.200 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2022 | 16 | 0.200 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 13 | 0.200 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 2 | 2018 | 18 | 0.190 |
Why?
|
| Biology | 1 | 2021 | 28 | 0.190 |
Why?
|
| Child | 15 | 2024 | 24105 | 0.180 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2022 | 126 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 88 | 0.180 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 62 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 137 | 0.170 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 12 | 0.170 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 13 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 9 | 0.170 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 21 | 0.170 |
Why?
|
| Azacitidine | 1 | 2019 | 56 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 333 | 0.170 |
Why?
|
| Hematopoiesis | 2 | 2022 | 220 | 0.160 |
Why?
|
| Humans | 29 | 2024 | 122432 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 102 | 0.160 |
Why?
|
| Lymphoma | 1 | 2022 | 323 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 193 | 0.160 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 65 | 0.160 |
Why?
|
| Arthralgia | 1 | 2018 | 45 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 178 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2019 | 223 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2018 | 63 | 0.150 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 19 | 0.140 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 117 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 53 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 270 | 0.140 |
Why?
|
| Intellectual Disability | 2 | 2022 | 1043 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.140 |
Why?
|
| Neutropenia | 1 | 2018 | 202 | 0.140 |
Why?
|
| Calreticulin | 1 | 2016 | 17 | 0.130 |
Why?
|
| Thrombopoietin | 1 | 2016 | 30 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 25 | 0.130 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2016 | 31 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 532 | 0.130 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 21 | 0.130 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 28 | 0.130 |
Why?
|
| CD8 Antigens | 1 | 2016 | 43 | 0.130 |
Why?
|
| Megakaryocytes | 1 | 2016 | 48 | 0.130 |
Why?
|
| CD5 Antigens | 1 | 2016 | 37 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 548 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 525 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 802 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2016 | 333 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 136 | 0.120 |
Why?
|
| Metformin | 1 | 2016 | 137 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2017 | 810 | 0.120 |
Why?
|
| Prognosis | 4 | 2019 | 4489 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 230 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 713 | 0.110 |
Why?
|
| Male | 15 | 2024 | 59590 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 332 | 0.110 |
Why?
|
| Female | 15 | 2024 | 64958 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2018 | 706 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1710 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2016 | 404 | 0.110 |
Why?
|
| Infant | 8 | 2020 | 12334 | 0.110 |
Why?
|
| Child, Preschool | 6 | 2019 | 13817 | 0.110 |
Why?
|
| World Health Organization | 2 | 2022 | 110 | 0.100 |
Why?
|
| Mutation | 3 | 2022 | 5776 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 790 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1250 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 670 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1392 | 0.090 |
Why?
|
| Gene Expression | 1 | 2016 | 1580 | 0.090 |
Why?
|
| Adolescent | 7 | 2024 | 18970 | 0.090 |
Why?
|
| Young Adult | 3 | 2023 | 8778 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4285 | 0.070 |
Why?
|
| Syndrome | 2 | 2018 | 1122 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1873 | 0.060 |
Why?
|
| Phenotype | 3 | 2018 | 4214 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 77 | 0.060 |
Why?
|
| Adult | 4 | 2023 | 28757 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 4511 | 0.050 |
Why?
|
| Hemolysis | 1 | 2023 | 103 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 126 | 0.050 |
Why?
|
| Haploidy | 1 | 2022 | 19 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 40 | 0.050 |
Why?
|
| CREB-Binding Protein | 1 | 2022 | 64 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 34 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 39 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 133 | 0.050 |
Why?
|
| Mice | 4 | 2022 | 17568 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 102 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 104 | 0.050 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 77 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 194 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 536 | 0.050 |
Why?
|
| Middle Aged | 3 | 2018 | 25641 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 193 | 0.050 |
Why?
|
| Prevalence | 2 | 2017 | 2372 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 255 | 0.040 |
Why?
|
| Aged | 2 | 2016 | 18785 | 0.040 |
Why?
|
| Skin | 1 | 2022 | 503 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 73 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 618 | 0.040 |
Why?
|
| Celecoxib | 1 | 2018 | 31 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 301 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 317 | 0.040 |
Why?
|
| Biopsy | 1 | 2022 | 1246 | 0.040 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2018 | 17 | 0.040 |
Why?
|
| Consanguinity | 1 | 2018 | 107 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1118 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 812 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 109 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2019 | 318 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2018 | 356 | 0.040 |
Why?
|
| Animals | 4 | 2022 | 33755 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 376 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2019 | 15856 | 0.030 |
Why?
|
| Guanidines | 1 | 2016 | 25 | 0.030 |
Why?
|
| Poly I-C | 1 | 2016 | 22 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 646 | 0.030 |
Why?
|
| Aldehydes | 1 | 2016 | 28 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 69 | 0.030 |
Why?
|
| Inactivation, Metabolic | 1 | 2016 | 33 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 14 | 0.030 |
Why?
|
| Reticulin | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2010 | 0.030 |
Why?
|
| Integrin beta3 | 1 | 2016 | 27 | 0.030 |
Why?
|
| Chromosome Breakage | 1 | 2016 | 168 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2016 | 19 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 637 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 130 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2533 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 1114 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 680 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 91 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1791 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2018 | 581 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 261 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 1574 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 619 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1413 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1472 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 816 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1997 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 517 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 2587 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 541 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 974 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3075 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1851 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2313 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 3773 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5013 | 0.020 |
Why?
|
| Diet | 1 | 2016 | 1106 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 1192 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3293 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6181 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8108 | 0.010 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 24 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 91 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12041 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 231 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1468 | 0.010 |
Why?
|